ME02667B - Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini - Google Patents
Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u mediciniInfo
- Publication number
- ME02667B ME02667B MEP-2017-74A MEP7417A ME02667B ME 02667 B ME02667 B ME 02667B ME P7417 A MEP7417 A ME P7417A ME 02667 B ME02667 B ME 02667B
- Authority
- ME
- Montenegro
- Prior art keywords
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 57
- 150000003839 salts Chemical class 0.000 claims 46
- 239000012453 solvate Substances 0.000 claims 46
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 10
- 102000015617 Janus Kinases Human genes 0.000 claims 7
- 108010024121 Janus Kinases Proteins 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003449 preventive effect Effects 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 102000006503 Janus Kinase 2 Human genes 0.000 claims 3
- 108010019437 Janus Kinase 2 Proteins 0.000 claims 3
- 102000006500 Janus Kinase 3 Human genes 0.000 claims 3
- 108010019421 Janus Kinase 3 Proteins 0.000 claims 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (52)
1. Spoj sljedeće opće formula [I]: , naznačen time što je Ra isti ili različiti i svaki od njih je: (1) C1-6 alkil, ili (2) atom halogena, n1 je cijeli broj, kojeg se bira između 0 do 4, Rb je isti ili različiti i svaki od njih je: (1) C1-6 alkil, ili (2) atom halogena, n2 je cijeli broj, kojeg se bira između 0 do 4, m1 je cijeli broj, kojeg se bira između 0 do 3, m2 je cijeli broj, kojeg se bira između 1 do 4, Xa = Xb je: (1) CH=CH, (2) N=CH, ili (3) CH=N, X je: (1) atom dušika, ili (2) C-Rd, gdje je Rd atom vodika ili atom halogena, Rc je skupina koju se bira između sljedećih (1) do (6): (1) atom vodika, (2) C1-6 alkil, koji može biti supstituiran s istim ili različitim 1 do 5 supstituenata, koje se bira između sljedećih skupina A, (3) -C(=O)-Rc1, (4) -C(=O)-O-Rc2, (5) -C(=O)-NRc3Rc4 gdje su Rc1, Rc2, Rc3 i Rc4 isti ili različiti i svaki od njih je: (i) atom vodika, ili (ii) C1-6 alkil, koji može biti supstituiran s istim ili različitim 1 do 5 supstituenata, koje se bira između sljedećih skupina A, ili (6) skupina formule: , gdje je Ya skupina koju se bira između sljedećih (i) do (iii): (i) C1-6 alkilen, (ii) -C(=O)-, ili (iii) -C(=O)-O-, prsten T je: (i) C6-10 aril, (ii) C3-10 cikloalkil, ili (iii) zasićeni monoheterociklil, gdje zasićeni monoheterociklil ima 1 do 4 heteroatoma, koje se bira između atoma dušika, atoma kisika ili atoma sumpora, kao i atome ugljika, a broj atoma koji čine prsten je 3 do 7, Rc5 je isti ili različiti i svaki od njih je: (i) cijano, ili (ii) nitro, p je cijeli broj, kojeg se bira između 0 do 4, skupina A je skupina koju čine: (a) hidroksil, (b) C1-6 alkoksi, (c) cijano, (d) C1-6 alkoksikarbonil, (e) C1-6 alkilkarboniloksi, i (f) C2-6 alkeniloksi, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što, u općoj formuli [I], n1 je cijeli broj, kojeg se bira između 0 do 2, n2 je cijeli broj, kojeg se bira između 0 do 2, m1 je cijeli broj, kojeg se bira između 0 do 3, m2 je cijeli broj, kojeg se bira između 1 do 3, X je: (1) atom dušika, ili (2) C-Rd, gdje je Rd atom halogena, Rc je skupina koju se bira između sljedećih (1) do (6): (1) atom vodika, (2) C1-6 alkil, supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A, (3) -C(=O)-Rc1, (4) -C(=O)-O-Rc2, (5) -C(=O)-NRc3Rc4 gdje je Rc1 C1-6 alkil, koji može biti supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A, Rc2 je C1-6 alkil, Rc3 je C1-6 alkil, koji može biti supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A, Rc4 je (i) atom vodika, ili (ii) C1-6 alkil, ili (6) skupina formule: , gdje je Ya skupina koju se bira između sljedećih (i) do (iii): (i) C1-6 alkilen, (ii) -C(=O)-, ili (iii) -C(=O)-O-, prsten T je: (i) fenil, (ii) C3-6 cikloalkil, ili (iii) pirolidinil, Rc5 je (i) cijano, ili (ii) nitro, p je cijeli broj, kojeg se bira između 0 ili 1, skupina A je skupina koju čine: (a) hidroksil, (b) C1-6 alkoksi, (c) cijano, (d) C1-6 alkoksikarbonil, (e) C1-6 alkilkarboniloksi, i (f) C2-6 alkeniloksi, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
3. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je m1 cijeli broj 0 ili 1, a m2 je cijeli broj 1 ili 2, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
4. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (1,2), naznačen time što je spoj opće formule [II]: , gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
5. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (0,2), naznačen time što je spoj opće formule [III]: , gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
6. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (0,1), naznačen time što je spoj opće formule [IV]: , gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
7. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što se kombinaciju (m1,m2) bira između (0,3), (2,1), (2,2) ili (3,2), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je Xa = Xb CH=CH, a X je atom dušika, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
9. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
10. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (1,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
11. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,1), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
12. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (2,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
13. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,2), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
14.Spoj u skladu s bilo kojim od patentnog zahtjeva 10 ili 12, naznačen time što je Ra metil ili atom fluora, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je Rc -C(=O)-Rc1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
16. Spoj u skladu s patentnim zahtjevom 15, naznačen time što je Rc1 C1-6 alkil, supstituiran s jednom hidroksilnom ili skupinom cijano, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je Rc -C(=O)-NRc3Rc4, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
18. Spoj u skladu s patentnim zahtjevom 17, naznačen time što je Rc3 C1-6 alkil, supstituiran s jednom skupinom cijano, a Rc4 je vodik, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
19.Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih kemijskih strukturnih formula: ili , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
20.Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih kemijskih strukturnih formula: ili , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
21. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
22. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
23. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
24. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
25. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
26. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
27. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je , ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
28. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, kao i farmaceutski prihvatljivu podlogu.
29. Inhibitor Janus kinaze, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
30. Inhibitor Janus kinaze u skladu s patentnim zahtjevom 29, naznačen time što je Janus kinaza Janus kinaza 3.
31. Inhibitor Janus kinaze u skladu s patentnim zahtjevom 29, naznačen time što je Janus kinaza Janus kinaza 2.
32. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijska bolest i kronična mijeloproliferativna bolest, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
33. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju reumatoidnog artritisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
34. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju psorijaze, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
35. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju suhog keratokonjunktivitisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
36. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju atopičnog dermatitisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
37. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u inhibiranju Janus kinaza.
38. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 37, naznačen time što je Janus kinaza Janus kinaza 3.
39. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 37, naznačen time što je Janus kinaza Janus kinaza 2.
40. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
41. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju reumatoidnog artritisa.
42. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju psorijaze.
43. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju suhog keratokonjunktivitisa.
44. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju atopičnog dermatitisa.
45. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji inhibitora Janus kinaze.
46. Upotreba u skladu s patentnim zahtjevom 45, naznačena time što je Janus kinaza Janus kinaza 3.
47. Upotreba u skladu s patentnim zahtjevom 45, naznačena time što je Janus kinaza Janus kinaza 2.
48. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
49. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje reumatoidnog artritisa.
50. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje psorijaze.
51. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje suhog keratokonjunktivitisa.
52. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje atopičnog dermatitisa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009179502 | 2009-07-31 | ||
| US27413709P | 2009-08-13 | 2009-08-13 | |
| PCT/JP2010/062873 WO2011013785A1 (ja) | 2009-07-31 | 2010-07-30 | 含窒素スピロ環化合物及びその医薬用途 |
| EP10804531.1A EP2460806B1 (en) | 2009-07-31 | 2010-07-30 | Nitrogen-containing spiro-ring compound and medicinal use of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02667B true ME02667B (me) | 2017-06-20 |
Family
ID=43529436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-74A ME02667B (me) | 2009-07-31 | 2010-07-30 | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US8609647B2 (me) |
| EP (3) | EP3181570A1 (me) |
| JP (9) | JP5520158B2 (me) |
| KR (1) | KR101773208B1 (me) |
| CN (1) | CN102510865B (me) |
| AR (1) | AR077497A1 (me) |
| AU (1) | AU2010278066B2 (me) |
| BR (1) | BR112012002157B1 (me) |
| CA (1) | CA2767899C (me) |
| CO (1) | CO6491052A2 (me) |
| CY (2) | CY1118747T1 (me) |
| DK (1) | DK2460806T3 (me) |
| ES (1) | ES2616705T3 (me) |
| FI (1) | FIC20250012I1 (me) |
| FR (1) | FR25C1010I2 (me) |
| HR (1) | HRP20170447T1 (me) |
| HU (2) | HUE033070T2 (me) |
| IL (1) | IL217048A (me) |
| LT (2) | LT2460806T (me) |
| ME (1) | ME02667B (me) |
| MX (1) | MX2012001313A (me) |
| MY (1) | MY163495A (me) |
| NL (1) | NL301321I2 (me) |
| NO (1) | NO2025014I1 (me) |
| NZ (1) | NZ597994A (me) |
| PE (1) | PE20121276A1 (me) |
| PL (1) | PL2460806T3 (me) |
| PT (1) | PT2460806T (me) |
| RS (1) | RS55913B1 (me) |
| RU (1) | RU2630694C2 (me) |
| SG (1) | SG176918A1 (me) |
| SI (1) | SI2460806T1 (me) |
| SM (1) | SMT201700166T1 (me) |
| TW (1) | TWI466885B (me) |
| WO (1) | WO2011013785A1 (me) |
| ZA (1) | ZA201200689B (me) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| KR101541086B1 (ko) * | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| ES2617339T3 (es) | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| PT2796460T (pt) | 2011-12-21 | 2018-11-05 | Shanghai hengrui pharmaceutical co ltd | Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| JP6427497B2 (ja) * | 2013-10-21 | 2018-11-21 | 日本たばこ産業株式会社 | 眼疾患の治療剤又は予防剤 |
| MX2016015613A (es) * | 2014-05-28 | 2017-04-13 | Astrazeneca Ab | Procesos para la preparacion de azd5363 e intermedios novedosos utilizados en el mismo. |
| CA2991020A1 (en) * | 2015-07-07 | 2017-01-12 | Japan Tobacco Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| MY196541A (en) * | 2015-09-24 | 2023-04-19 | Leo Pharma As | Treatment of Alopecia Areata |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| DK3405197T3 (da) | 2016-01-21 | 2023-11-27 | Leo Pharma As | Topisk behandling af håndeksem |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| KR20190084299A (ko) * | 2016-11-23 | 2019-07-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤로 6-원 헤테로방향족 고리 유도체의 제조 방법 및 그의 중간체 |
| BR112019012688A2 (pt) * | 2016-12-21 | 2019-11-19 | Japan Tobacco Inc | método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo |
| EP3559003B1 (en) * | 2016-12-21 | 2022-08-24 | Japan Tobacco Inc. | Crystalline forms of a janus kinase inhibitor |
| TWI790218B (zh) * | 2016-12-21 | 2023-01-21 | 日商日本煙草產業股份有限公司 | 7Ｈ－吡咯并[2,3－ｄ]嘧啶衍生物的製造方法及其共結晶 |
| WO2018134352A1 (en) | 2017-01-20 | 2018-07-26 | Leo Pharma A/S | Bicyclic amines as novel jak kinase inhibitors |
| RU2761626C2 (ru) * | 2017-02-03 | 2021-12-13 | Лео Фарма А/С | ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ |
| US11149039B2 (en) * | 2017-10-10 | 2021-10-19 | Biogen Inc. | Process for preparing spiro derivatives |
| PE20211455A1 (es) * | 2018-01-31 | 2021-08-05 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| CN112384514A (zh) * | 2018-07-06 | 2021-02-19 | 利奥制药有限公司 | 作为janus激酶抑制剂的新的氨基-咪唑并嘧啶衍生物及其药物用途 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| KR20220008893A (ko) | 2019-05-15 | 2022-01-21 | 레오 파마 에이/에스 | 피부 홍반성 루푸스의 치료 |
| KR20220044288A (ko) * | 2019-08-07 | 2022-04-07 | 로토 세이야쿠 가부시키가이샤 | 누액 분비 촉진용 안과 조성물 |
| CN119367282A (zh) * | 2019-12-27 | 2025-01-28 | 乐敦制药株式会社 | 水性组合物 |
| CN111560021B (zh) * | 2020-06-30 | 2023-05-26 | 上海鲲博玖瑞医药科技发展有限公司 | 一种德高替尼中间体及其制备方法 |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| CN111574540B (zh) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | 一种德高替尼的制备方法 |
| WO2022117075A1 (zh) * | 2020-12-04 | 2022-06-09 | 广州费米子科技有限责任公司 | 氮杂并环化合物、其制备方法及其用途 |
| WO2022143629A1 (zh) * | 2020-12-29 | 2022-07-07 | 上海岸阔医药科技有限公司 | 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法 |
| WO2023202989A1 (en) | 2022-04-20 | 2023-10-26 | Leo Pharma A/S | Treatment of frontal fibrosing alopecia |
| AU2024229918A1 (en) | 2023-02-28 | 2025-09-18 | Assia Chemical Industries Ltd. | Solid state forms of delgocitinib and process thereof |
| WO2024194105A1 (en) | 2023-03-17 | 2024-09-26 | Leo Pharma A/S | A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema |
| WO2024225445A1 (en) | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
| WO2025085050A1 (en) * | 2023-10-16 | 2025-04-24 | Leo Pharma A/S | Treatment of frontal fibrosing alopecia |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4611524B2 (ja) | 1998-06-02 | 2011-01-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピロロ［２，３ｄ］ピリミジン組成物およびその使用 |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| SK286640B6 (sk) | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
| DE60037345T2 (de) * | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| DK1519939T5 (da) * | 2002-07-05 | 2011-01-24 | Targacept Inc | N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf |
| JPWO2005047286A1 (ja) * | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| EP2354140A1 (en) * | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| WO2008029237A2 (en) | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
| CN101563323B (zh) | 2006-12-22 | 2012-07-04 | 弗·哈夫曼-拉罗切有限公司 | 螺-哌啶衍生物 |
| CL2008000467A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| CN101679440A (zh) * | 2007-04-02 | 2010-03-24 | 帕劳制药股份有限公司 | 作为jak3抑制剂的吡咯并嘧啶衍生物 |
| US20100298289A1 (en) * | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| TW200940542A (en) | 2008-01-09 | 2009-10-01 | Array Biopharma Inc | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| JP2018028525A (ja) * | 2016-08-15 | 2018-02-22 | 小野 信行 | イオンレーザーと重水素を利用した核融合炉 |
| JP6229778B2 (ja) * | 2016-09-21 | 2017-11-15 | サミー株式会社 | 遊技機 |
-
2010
- 2010-07-22 TW TW99124110A patent/TWI466885B/zh active
- 2010-07-23 AR ARP100102681A patent/AR077497A1/es active IP Right Grant
- 2010-07-30 EP EP17150170.3A patent/EP3181570A1/en not_active Withdrawn
- 2010-07-30 SI SI201031426A patent/SI2460806T1/sl unknown
- 2010-07-30 US US12/847,025 patent/US8609647B2/en active Active
- 2010-07-30 SG SG2011094117A patent/SG176918A1/en unknown
- 2010-07-30 EP EP10804531.1A patent/EP2460806B1/en active Active
- 2010-07-30 RS RS20170305A patent/RS55913B1/sr unknown
- 2010-07-30 PT PT108045311T patent/PT2460806T/pt unknown
- 2010-07-30 ES ES10804531.1T patent/ES2616705T3/es active Active
- 2010-07-30 MY MYPI2012000155A patent/MY163495A/en unknown
- 2010-07-30 PL PL10804531T patent/PL2460806T3/pl unknown
- 2010-07-30 AU AU2010278066A patent/AU2010278066B2/en active Active
- 2010-07-30 SM SM20170166T patent/SMT201700166T1/it unknown
- 2010-07-30 BR BR112012002157-5A patent/BR112012002157B1/pt active IP Right Grant
- 2010-07-30 WO PCT/JP2010/062873 patent/WO2011013785A1/ja not_active Ceased
- 2010-07-30 KR KR1020127001455A patent/KR101773208B1/ko active Active
- 2010-07-30 NZ NZ597994A patent/NZ597994A/xx unknown
- 2010-07-30 PE PE2012000097A patent/PE20121276A1/es active IP Right Grant
- 2010-07-30 JP JP2010171260A patent/JP5520158B2/ja active Active
- 2010-07-30 RU RU2012106344A patent/RU2630694C2/ru active
- 2010-07-30 MX MX2012001313A patent/MX2012001313A/es active IP Right Grant
- 2010-07-30 CN CN201080034068.1A patent/CN102510865B/zh active Active
- 2010-07-30 CA CA2767899A patent/CA2767899C/en active Active
- 2010-07-30 HU HUE10804531A patent/HUE033070T2/hu unknown
- 2010-07-30 LT LTEP10804531.1T patent/LT2460806T/lt unknown
- 2010-07-30 DK DK10804531.1T patent/DK2460806T3/en active
- 2010-07-30 ME MEP-2017-74A patent/ME02667B/me unknown
- 2010-07-30 HR HRP20170447TT patent/HRP20170447T1/hr unknown
- 2010-07-30 EP EP21159390.0A patent/EP3858349A1/en active Pending
-
2011
- 2011-12-18 IL IL217048A patent/IL217048A/en active IP Right Grant
-
2012
- 2012-01-18 CO CO12006869A patent/CO6491052A2/es active IP Right Grant
- 2012-01-27 ZA ZA2012/00689A patent/ZA201200689B/en unknown
-
2013
- 2013-11-12 US US14/077,446 patent/US20140187534A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077850A patent/JP2014141516A/ja active Pending
-
2015
- 2015-11-17 JP JP2015224910A patent/JP2016029104A/ja not_active Ceased
-
2016
- 2016-11-02 JP JP2016214954A patent/JP2017019877A/ja not_active Ceased
-
2017
- 2017-03-20 CY CY20171100348T patent/CY1118747T1/el unknown
-
2018
- 2018-02-21 JP JP2018028525A patent/JP2018111701A/ja not_active Ceased
-
2019
- 2019-12-04 JP JP2019219283A patent/JP2020033384A/ja not_active Withdrawn
-
2021
- 2021-09-06 JP JP2021144545A patent/JP2021183653A/ja not_active Withdrawn
- 2021-12-21 US US17/557,174 patent/US20230023377A1/en not_active Abandoned
-
2023
- 2023-05-05 US US18/143,720 patent/US20240150367A1/en not_active Abandoned
- 2023-08-07 JP JP2023128376A patent/JP2023138641A/ja not_active Withdrawn
-
2025
- 2025-02-28 FR FR25C1010C patent/FR25C1010I2/fr active Active
- 2025-02-28 CY CY2025008C patent/CY2025008I1/el unknown
- 2025-02-28 FI FIC20250012C patent/FIC20250012I1/fi unknown
- 2025-03-03 HU HUS2500013C patent/HUS2500013I1/hu unknown
- 2025-03-03 LT LTPA2025511C patent/LTPA2025511I1/lt unknown
- 2025-03-04 NO NO2025014C patent/NO2025014I1/no unknown
- 2025-03-04 NL NL301321C patent/NL301321I2/nl unknown
- 2025-05-08 JP JP2025077764A patent/JP2025109780A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02667B (me) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
| JP2011046700A5 (me) | ||
| NZ710411A (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| RU2012122020A (ru) | N-содержащие гетероарильные производные в качестве ингибиторов jak3 киназы | |
| ME02325B (me) | Benzoeve kiseline (1-fenil-2-piridin-4-il)-etil estri kao inhibitori fosfodiesteraze | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| CO2017001603A2 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| JP2010535722A5 (me) | ||
| EA201071232A1 (ru) | Триазины как ингибиторы киназы pi3 и mtor | |
| EA201001618A1 (ru) | Ингибиторы syk протеинкиназ | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| RU2018121288A (ru) | Ингибиторы ионного канала, фармацевтические составы и применение | |
| RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| NZ603643A (en) | Purinone derivative | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| EA201001017A1 (ru) | 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы | |
| EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
| IN2014DN07283A (me) |